These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31915372)

  • 1. New approaches in viraemic organ transplantation and antiviral therapies.
    Holmes JA; Chung RT
    Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):78-79. PubMed ID: 31915372
    [No Abstract]   [Full Text] [Related]  

  • 2. Mavyret and Vosevi--two new combinations for chronic HCV infection.
    Med Lett Drugs Ther; 2017 Oct; 59(1531):166-170. PubMed ID: 28977807
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
    Vermehren J; Serfert Y; Cornberg M; Stoehr A; Klinker H; Simon KG; Teuber G; Deterding K; Schulze Zur Wiesch J; Jung MC; Manns MP; Zeuzem S; Wedemeyer H; Sarrazin C
    Z Gastroenterol; 2020 Sep; 58(9):841-846. PubMed ID: 32947629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
    Voaklander R; Jacobson IM
    Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):789-795. PubMed ID: 28673106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
    Cory TJ; Mu Y; Gong Y; Kodidela S; Kumar S
    Expert Opin Pharmacother; 2018 May; 19(7):749-757. PubMed ID: 29634360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
    Besandre R; Liu HW
    Biochemistry; 2018 Feb; 57(5):479-480. PubMed ID: 29185714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Oral HCV Drug.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):20. PubMed ID: 29076849
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
    Gane EJ; Kowdley KV; Pound D; Stedman CA; Davis M; Etzkorn K; Gordon SC; Bernstein D; Everson G; Rodriguez-Torres M; Tsai N; Khalid O; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Tong M; Chung RT; Beavers K; Poulos JE; Kwo PY; Nguyen MH
    Gastroenterology; 2016 Nov; 151(5):902-909. PubMed ID: 27486033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
    Younossi ZM; Stepanova M; Gordon S; Zeuzem S; Mann MP; Jacobson I; Bourliere M; Cooper C; Flamm S; Reddy KR; Kowdley K; Younossi I; Hunt S
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):567-574.e6. PubMed ID: 29155352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
    Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
    J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Pawlotsky JM
    Semin Liver Dis; 2019 Jul; 39(3):354-368. PubMed ID: 31041789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
    Pillai AA; Anania FA; Pearlman BL
    Am J Gastroenterol; 2016 Dec; 111(12):1854-1856. PubMed ID: 27924099
    [No Abstract]   [Full Text] [Related]  

  • 15. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
    Summers BB
    Drugs Today (Barc); 2018 Apr; 54(4):255-268. PubMed ID: 29869647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Foster GR; Mangia A; Sulkowski M
    N Engl J Med; 2016 Apr; 374(17):1687-8. PubMed ID: 27119242
    [No Abstract]   [Full Text] [Related]  

  • 17. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Assy N; Barhoum M
    N Engl J Med; 2016 Apr; 374(17):1687. PubMed ID: 27119243
    [No Abstract]   [Full Text] [Related]  

  • 18. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Curry MP; Charlton M
    N Engl J Med; 2016 Apr; 374(17):1688. PubMed ID: 27135094
    [No Abstract]   [Full Text] [Related]  

  • 19. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Feld JJ; Zeuzem S
    N Engl J Med; 2016 Apr; 374(17):1688-9. PubMed ID: 27135095
    [No Abstract]   [Full Text] [Related]  

  • 20. Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia.
    Sharara AI; Rustom LBO; Marrache M; Rimmani HH; Bou Daher H; Koussa S; Taher A
    Am J Hematol; 2019 Feb; 94(2):E43-E45. PubMed ID: 30394575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.